Patents by Inventor Paul W. Burridge

Paul W. Burridge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITION OF SLC TRANSPORTER ACTIVITY OR EXPRESSION TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY
    Publication number: 20230190773
    Abstract: Disclosed are methods, pharmaceutical compositions, kits, and systems for treating or preventing cardiotoxicity in a subject undergoing treatment with an anthracycline chemotherapeutic agent. The methods, pharmaceutical compositions, kits, and systems typically include or utilize a therapeutic agent that inhibits the activity or expression of the solute transporter SLC28A3.
    Type: Application
    Filed: October 31, 2022
    Publication date: June 22, 2023
    Inventors: Paul W. Burridge, Tarek Magdy Shehata Mohamed
  • RETINOIC ACID RECEPTOR GAMMA AGONISTS TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY
    Publication number: 20220016148
    Abstract: Disclosed are methods, pharmaceutical compositions, kits, and systems for treating or preventing cardiotoxicity in a subject undergoing treatment with an anthracycline chemotherapeutic agent. The methods, pharmaceutical compositions, kits, and systems typically include or utilize an agonist of the retinoic acid receptor gamma (RARG).
    Type: Application
    Filed: October 4, 2021
    Publication date: January 20, 2022
    Inventor: Paul W. Burridge
  • Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity
    Patent number: 11135236
    Abstract: Disclosed are methods, pharmaceutical compositions, kits, and systems for treating or preventing cardiotoxicity in a subject undergoing treatment with an anthracycline chemotherapeutic agent. The methods, pharmaceutical compositions, kits, and systems typically include or utilize an agonist of the retinoic acid receptor gamma (RARG).
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: October 5, 2021
    Assignee: Northwestern University
    Inventor: Paul W. Burridge
  • RETINOIC ACID RECEPTOR GAMMA AGONISTS TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY
    Publication number: 20190358250
    Abstract: Disclosed are methods, pharmaceutical compositions, kits, and systems for treating or preventing cardiotoxicity in a subject undergoing treatment with an anthracycline chemotherapeutic agent. The methods, pharmaceutical compositions, kits, and systems typically include or utilize an agonist of the retinoic acid receptor gamma (RARG).
    Type: Application
    Filed: April 5, 2019
    Publication date: November 28, 2019
    Applicant: Northwestern University
    Inventor: Paul W. Burridge
  • Cardiomyocytes From Induced Pluripotent Stem Cells From Patients and Methods of Use Thereof
    Publication number: 20170058263
    Abstract: Human somatic cells obtained from individuals with a genetic heart condition are reprogrammed to become induced pluripotent stem cells (iPS cells), and differentiated into cardiomyocytes for use in analysis, screening programs, and the like.
    Type: Application
    Filed: June 10, 2016
    Publication date: March 2, 2017
    Inventors: Ning Sun, Michael T. Longaker, Robert C. Robbins, Joseph Wu, Feng Lan, Andrew Stephen Lee, Paul W. Burridge
  • Cardiomyocytes from induced pluripotent stem cells from patients and methods of use thereof
    Patent number: 9395354
    Abstract: Human somatic cells obtained from individuals with a genetic heart condition are reprogrammed to become induced pluripotent stem cells (iPS cells), and differentiated into cardiomyocytes for use in analysis, screening programs, and the like.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 19, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ning Sun, Michael T. Longaker, Robert C. Robbins, Joseph Wu, Feng Lan, Andrew Stephen Lee, Paul W. Burridge
  • Chemically defined production of cardiomyocytes from pluripotent stem cells
    Patent number: 9234176
    Abstract: Methods are provided for producing a cardiomyocyte population from a mammalian pluripotent stem cell population. Aspects of the methods include using a Wnt signaling agonist and antagonist, each in minimal media, to modulate Wnt signaling. Also provided are kits for practicing the methods described herein.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: January 12, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Joseph Wu, Robert C. Robbins, Paul W. Burridge
  • CHEMICALLY DEFINED PRODUCTION OF CARDIOMYOCYTES FROM PLURIPOTENT STEM CELLS
    Publication number: 20140134733
    Abstract: Methods are provided for producing a cardiomyocyte population from a mammalian pluripotent stem cell population. Aspects of the methods include using a Wnt signaling agonist and antagonist, each in minimal media, to modulate Wnt signaling. Also provided are kits for practicing the methods described herein.
    Type: Application
    Filed: November 13, 2013
    Publication date: May 15, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Joseph Wu, Robert C. Robbins, Paul W. Burridge
  • CARDIOMYOCYTES FROM INDUCED PLURIPOTENT STEM CELLS FROM PATIENTS AND METHODS OF USE THEREOF
    Publication number: 20130029866
    Abstract: Human somatic cells obtained from individuals with a genetic heart condition are reprogrammed to become induced pluripotent stem cells (iPS cells), and differentiated into cardiomyocytes for use in analysis, screening programs, and the like.
    Type: Application
    Filed: July 20, 2012
    Publication date: January 31, 2013
    Inventors: Ning Sun, Michael T. Longaker, Robert C. Robbins, Joseph Wu, Feng Lan, Andrew Stephen Lee, Paul W. Burridge